Japan’s Health Ministry panel cleared plan for approval Novavax IncNVAX The COVID-19 vaccine, which is expected to be the fourth such vaccine to be approved in Japan.
It will be available for the first and second shots with a three-week interval.
The Novavax product is a recombinant protein vaccine that uses parts of the coronavirus protein.
Related:Early Data Shows Novavax’s COVID-19 Vaccine Triggers Immune Response to Omicron.
The mechanism of the vaccine is different from the three already approved in Japan – Pfizer Inc DFP / BioNTech SE BNTXModerna inc. mrnaand AstraZeneca plc AZN.
Novavax vials can be refrigerated at 2-8 degrees Celsius, making them easy to transport and manage.
Read also :Novavax’s COVID-19 Reached FDA Clearance.
Takeda Pharmaceutical Co Ltd TAKS is responsible for the distribution of the Novavax vaccine in Japan.
The Japanese government has entered into a contract with Takeda to supply 150 million doses of vaccines in 2022.
Price Action: NVAX shares are down 5.84% at $55.15 when last checked on Monday.
